Methods of Treatment and/or Prevention of Disorders and Symptoms Related to BKCa and/or SK Channelopathies
Summary
USPTO granted patent US12605367B2 on April 21, 2026, covering compounds and compositions for treating neurological and non-neurological channelopathies caused by defects in calcium-activated potassium channels. The patent lists 14 claims targeting conditions including Fragile X Syndrome, autism spectrum disorders, Angelman syndrome, and other neuropathic and neurodegenerative diseases. The filing date was September 15, 2020, with application number 17760612.
What changed
USPTO granted patent US12605367B2 on April 21, 2026, covering therapeutic compounds and methods for treating neurological channelopathies including Fragile X Syndrome, autism spectrum disorders, Angelman syndrome, Williams-Beuren syndrome, and other neuropsychiatric and neurodegenerative conditions related to BKCa and SK potassium channel defects. The patent contains 14 claims and names four inventors.
Pharmaceutical and biotech companies developing treatments for neurological channelopathies or working with BKCa/SK channel modulators should review this patent for potential freedom-to-operate considerations. Generic drug manufacturers and therapeutic developers in related neurological indication areas should monitor USPTO records for similar patent filings in the channelopathy space.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods of treatment and/or prevention of disorders and symptoms related to BKCa and/or SK channelophathies
Grant US12605367B2 Kind: B2 Apr 21, 2026
Inventors
Susanna Pietropaolo, Wilhelmus Crusio, Valérie Lemaire, Eric Louette
Abstract
The present invention relates to compounds and compositions for use in a method of treating and/or preventing neurological or non-neurological channelopathies, i.e., pathologies which are caused specifically by defects in some of the calcium-activated potassium channels. Specific neurological channelopathies and/or synaptopathies targeted by the present invention include specific neuropsychiatric pathologies, such as particularly Fragile X Syndrome (FXS), Angelman syndrome, Williams-Beuren syndrome, autism, Autism spectrum disorders (ASDs), hyperacusis, Smith-Magenis syndrome, Prader-Willi syndrome, 7q11.23 duplication syndrome, and cri-du-chat syndrome, as well as other neuropathic disorders such as trembling, epilepsy and neuropathic pains associated and neurodegenerative diseases such as Parkinson's and Alzheimer diseases. Compounds, compositions and methods of the present invention are also particularly useful and efficient in alleviating neurological symptoms common to these neuropsychiatric pathologies.
CPC Classifications
A61K 31/423 A61K 31/433 A61P 25/28
Filing Date
2020-09-15
Application No.
17760612
Claims
14
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.